Advanced Malignant Solid Tumors
Conditions
Interventions
Dose escalation cohorts:JSKN022 will be administered via intravenous infusion at the protocol-specified frequency, with dosage calculated based on the subject’s body weight. Based on interim safety, P
Dose optimization cohorts:During or after dose escalation, upon SMC approval, several dose levels and administration frequencies that have completed DLT observation may be selected for dose optimizati
Sponsors
Sun Yat-sen University Cancer Center
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1. Voluntarily participate and sign the informed consent form. 2. Age >= 18 years old, male or female. 3. Eastern Cooperative Oncology Group performance status (ECOG PS) score of 0 or 1. 4. Expected survival >= 3 months. 5. Histologically or cytologically confirmed malignant solid tumors confirmed by histology and/or cytology, who have failed previous standard treatment (disease progression), are intolerant to standard treatment, or have no access to standard treatment. 6. At least one measurable lesion at baseline according to RECIST 1.1 criteria. 7. Adequate organ function. 8. Agree to provide Recently archived or fresh tumor tissue samples. 9. Female subjects of childbearing potential or male subjects whose partners are of childbearing potential agree to use effective contraceptive measures. 10. Female subjects of childbearing potential must have a negative serum/urine pregnancy test within 7 days before the first dose. 11. Be able and willing to comply with the visits, treatment plans, laboratory tests, and other study-related procedures specified in the study protocol. 12. Adequate washout period of previous therapy before the first dose.
Exclusion criteria
Exclusion criteria: 1. Complicated with other malignant tumors within 5 years before the first dose, except for tumor types that have achieved clinical cure through local treatment with extremely low recurrence risk or tumor types with disease-free survival >= 5 years after radical treatment and extremely low recurrence/metastasis risk. 2. History of brainstem, meningeal metastasis, spinal cord metastasis or compression, or carcinomatous meningitis; presence of active brain metastasis. 3. Screening imaging shows tumor invasion, compression, or occurrence in surrounding important organs or risk of esophagotracheal fistula or esophagopleural fistula, except those judged by the investigator and medical monitor to not affect the patient's enrollment and administration. 4. Presence of clinically severe respiratory impairment caused by pulmonary disease complications. 5. Presence of the risk factors related to interstitial lung disease (ILD) or non-infectious pneumonia: 6. Presence of cardiovascular and cerebrovascular diseases or cardiovascular and cerebrovascular risk factors. 7. Gastrointestinal abnormalities with obvious clinical manifestations. 8. Active autoimmune diseases requiring systemic treatment within the past two years. 9. Significant serous effusion. 10. Uncontrolled infection. 11. Require regular glucocorticoid or immunosuppressive therapy. 12. Received live vaccines within 28 days before the first dose, or plan to receive live vaccines during the study period. 13. Prior treatment with antibody-drug conjugates containing topoisomerase I inhibitors. 14. Previous occurrence of grade >= 3 immune-related adverse events during immunotherapy. 15. Toxicity of previous anti-tumor treatment has not fully or partially recovered. 16. Known allergy to any component of the study drug, or history of severe allergic reactions to other antibody drugs. 17. Pregnant and/or lactating women, or planning to become pregnant during the study period. 18. Known history of mental illness, substance abuse, alcoholism, etc., or other situations that the investigator deems may affect the safety or compliance of the study drug treatment. 19. Local or systemic diseases caused by non-malignant tumors, or diseases or symptoms secondary to tumors, which may lead to high medical risks and/or uncertainty in survival assessment, such as tumor-related leukemia reaction (white blood cell count > 20×10^9/L), cachexia manifestations, etc. 20. Any other previous or current diseases, treatments, or laboratory test abnormalities that the investigator deems may confuse the study results, affect the patient's full participation in the study, or participation in the study may not be in the best interest of the patient.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The safety and tolerability of JSKN022 in patients with advanced malignant solid tumors;The maximum tolerated dose (MTD) and/or recommended phase II dose (RP2D) of JSKN022; | — |
Secondary
| Measure | Time frame |
|---|---|
| Anti-tumor activity of JSKN022;The pharmacokinetic (PK) profile of JSKN022;The immunogenicity of JSKN022; | — |
Countries
China
Contacts
Public ContactRuihua Xu
Sun Yat-sen University Cancer Center
Outcome results
None listed